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Summary Leptospirosis is a zoonosis of worldwide distribution, spread by the urine of infected animals. It is a
major public health problem, especially in developing countries, where circumstances for transmission
are most favourable. The clinical picture varies from mild disease to a severe illness with haemostatic
derangements and multiorgan failure eventually leading to death. Although the haemorrhagic
complications of severe disease are serious, the pathophysiology is scarcely elucidated. The complex
mechanisms involved in inflammation-induced coagulation activation are extensively studied in various
infectious diseases, i.e. Gram-negative sepsis. Tissue factor-mediated coagulation activation, impairment
of anticoagulant and fibrinolytic pathways in close concert with the cytokine network are thought to be
important. But for human leptospirosis, data are limited. Because of the growing interest in this field, the
impact of leptospirosis, and the availability of new therapeutic strategies, we reviewed the evidence
regarding the role of coagulation in leptospirosis and provide suggestions for future research.
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Introduction
Leptospirosis is a zoonosis of global importance (Vinetz
2001) caused by infection with pathogenic Leptospira
species. Transmission occurs where humans come into
direct or indirect contact with urine of infected animals
(Levett 2001). Due to the longer survival of leptospires in
warm and humid conditions, leptospirosis is predomin-
antly common in the (sub)tropics but transmission occurs
in both industrialized and developing countries (Bharti
et al. 2003). The incidence of leptospirosis during out-
breaks and in high exposure risk groups is estimated to
exceed 100/100 000 persons/year (WHO). However, this
incidence is probably heavily underestimated due to the
lack of diagnostic tools in endemic areas and the atypical
presentation of the disease, resembling many other illnes-
ses, such as dengue and other haemorrhagic fevers
(Ko et al. 1999; Sanders et al. 1999; Levett et al. 2000).
The clinical picture of leptospirosis varies from a febrile
illness of sudden onset, to a potentially fatal disease
complicated by jaundice, renal failure and serious
haemorrhages. Pulmonary haemorrhage has become
recognized among the most important manifestation of
human leptospirosis and is increasingly reported over the
world (Park et al. 1989; O’Neil et al. 1991; Zaki & Shieh
1996; Trevejo et al. 1998; Yersin et al. 2000; Wagenaar
et al. 2004). Other bleeding manifestations include: hae-
maturia, haematemesis, melaena, epistaxis, petechiae, ec-
chymoses, bleeding from venipuncture sites and
subarachnoid bleeding (Theilen et al. 2002). Pathologist’s
findings in autopsies of humans and animals underline the
bleeding tendency, and show widespread haemorrhages
throughout the body (Guedes e Silva et al. 1980; Pereira da
Silva et al. 1995; Nally et al. 2004; Pereira et al. 2005).
Although the haemorrhagic potential of leptospirosis
was noted by Weil (1886) as early as 1886, its patho-
physiology is still not clearly elucidated, particularly
regarding the cause and mechanisms of bleeding. Theor-
etically, bleeding may be the result of a defect in the
primary haemostasis or a dysbalance in secondary
haemostasis by depletion of coagulation proteins because
of enhanced coagulation or by activated fibrinolysis.
Regarding therapy, there is some evidence that antibiotic
treatment of leptospirosis may be beneficial, even given in
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late stage of disease (Watt et al. 1988). However there is an
urge to improve therapy and supportive care, as severe
leptospirosis still accounts for many deaths. Novel thera-
peutic agents intervening with the coagulation and cyto-
kine cascades may be beneficial. Hence, understanding of
the pathogenic mechanisms is crucial. In this study, we
review current insights on the involvement of abnormal
haemostasis in the pathophysiology of leptospirosis. What
is the evidence for defects in primary haemostasis and is
there any proof for exaggerated coagulation activation and
impaired fibrinolysis?
Method
Citations were retrieved from PubMed and MEDLINE
databases, and from locally accessible files of the KIT
Royal Tropical Institute library, Amsterdam, the Nether-
lands. The single terms ‘Leptospirosis’, ‘Weil disease’,
‘Hemostasis’, ‘Coagulation’, ‘Fibrinolysis’, ‘Inflammation’,
‘Endothelium’, ‘Thrombocytopenia’, ‘Coagulation Protein
Disorders’, ‘Disseminated Intravascular Coagulation’,
‘Blood Coagulation Disorders’, were used and combina-
tions of these terms. Titles, abstracts and references were
scanned for relevance on the current topic. Both English
and German language papers were reviewed.
Clinical features of leptospirosis
The symptoms seen in human leptospirosis are very
diverse. Most infections are mild and only a minority of
infected patients will seek medical attention. These usually
present with a febrile illness and accompanying symptoms
may include: chills, headache, myalgia (especially intense
calve pain), gastrointestinal complaints and mild haemor-
rhagic manifestations, such as conjunctival suffusion. Skin
symptoms, such as rash are seen less often and may be
misdiagnosed as scrub-typhus or viral infections.
The most severe presentation of icteric human leptospi-
rosis, often referred to as Weil’s disease, is characterized by
jaundice, renal failure, extensive haemorrhage and a high
case fatality rate between 5% and 15% (Bharti et al.
2003). Icteric leptospirosis occurs between 5% and 10% of
all leptospirosis cases (Heath et al. 1965) and is thought
not to be the result of hepatocellular damage but rather
sepsis-related cholestasis (Moseley 1997). Raises in
transaminase levels are usually moderate and the liver
function will restore to normal during recovery. Thromb-
ocytopenia is often reported but is not directly correlated
with a higher incidence of haemorrhage in leptospirosis.
However, thrombocytopenia is positive correlated with the
development of acute renal failure and the age of the
patients (Edwards et al. 1982). Thrombocytopenia and
renal failure were found not to be associated with higher
mortality in another retrospective study among 60 cases of
leptospirosis (Raoult et al. 1983). The renal failure seen in
leptospirosis is unique because it is hypokalemic and
usually non-oliguric (Seguro et al. 1990). When oliguria
develops nonetheless, it is a significant predictor of
mortality (Daher et al. 1999). Leptospirosis can also
severely affect the lungs. Pulmonary symptoms may
include cough, dyspnoea and haemoptysis and may even-
tually develop into adult respiratory distress syndrome
(ARDS) and severe pulmonary haemorrhage syndrome
(SPHS). Haemoptysis may not be evident until patients are
intubated and therefore clinicians should suspect SPHS in
all patients with signs of respiratory distress, also without
signs of haemoptysis (McBride et al. 2005). Some evidence
suggests that an autoimmune process is responsible for the
damage to the pulmonary endothelium (Nally et al. 2004;
McBride et al. 2005; Pereira et al. 2005). The severity of
respiratory disease is not related to the presence of jaundice
(Hill & Sanders 1997). Other clinical manifestations of
leptospirosis reported include aseptic meningitis, cardiac
involvement with ECG alterations and myocarditis and
ocular involvement with autoimmune-associated anterior
uveitis.
Haemorrhagic syndromes in leptospirosis
Infection-associated activation of the coagulation cascade
may lead to a wide spectrum of clinical effects, ranging
from clinical insignificant rise in laboratory markers to
severe thrombo-haemorrhagic syndromes, such as disse-
minated intravascular coagulation (DIC), haemolytic
uraemic syndrome (HUS), thrombotic thrombocytopenic
purpura (TTP) and vasculitis (van Gorp et al. 1999).
Patients suffering from these disorders may present with
bleeding, thrombosis or both. Various haemostatic mark-
ers are used to discriminate between these syndromes.
Some of these markers are summarized in Table 1.
Is there any proof that leptospirosis patients suffer
from thrombo-haemorrhagic complications? Considering
pathological findings, vasculitis with endothelial damage
and inflammatory infiltrates composed of monocytic
cells, plasma cells, histiocytes and neutrophils is thought
to be the pathological hallmark in both human and
animal leptospirosis (Levett 2001). In addition, petechial
haemorrhages are commonly found and may be exten-
sive. Other findings include: pulmonary haemorrhages,
intrahepatic cholestasis, hypertrophy and hyperplasia of
Kupffer cells, interstitial nephritis, coronary arteritis and
haemorrhagic necrosis in skeletal muscles (Higgins &
Cousineau 1977; Guedes e Silva et al. 1980; Pereira da
Silva et al. 1995; Levett 2001; Nally et al. 2004; Pereira
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et al. 2005; Yang et al. 2006). The intense intra-alveolar
haemorrhages seem to be unique for leptospirosis, the
morphological features include interstitial inflammatory
infiltrates and extravasations of red blood cells from the
capillary bed, which are not seen in other capillary
leakage syndromes, such as dengue haemorrhagic fever
and pulmonary Hanta (Pereira et al. 2005).
Whether thrombocytopenia is in any way due to DIC is
a topic of ongoing research in the field of leptospirosis.
DIC is a potentially fatal syndrome where activation of
the coagulation cascade results in microvascular throm-
bosis together with a macrovascular bleeding tendency
because of depletion from blood cells and proteins,
including fibrinogen. Fibrin deposition is the result of
tissue factor-mediated thrombin formation and simulta-
neous inhibition of anticoagulant mechanisms, such as the
protein C system. In chorus, high levels of plasminogen
activator inhibitor type (PAI)-1, a strong inhibitor of
fibrinolysis, and the effects of proinflammatory cytokines
contribute to enhance fibrin deposition (Levi & ten Cate
1999). This combination of events may lead to multiorgan
failure (MOF) and eventually death. DIC can be caused
by several stimuli, such as bacteria, viruses and other
invading pathogens. Some animal models showed evi-
dence of DIC in leptospirosis-infected guinea pigs
(Higgins & Cousineau 1977; Pereira da Silva et al. 1995)
and one experimental model showed DIC in infected dogs
(Navarro & Kociba 1982), while others did not (Nally
et al. 2004; Yang et al. 2006). Unfortunately, large
clinical studies related to the association of DIC and
leptospirosis has not been reported. In DIC levels of fibrin
and its precursor protein fibrinogen, are usually low due
to increased consumption. Several reports concerning
leptospirosis demonstrated increased levels of plasma
fibrinogen. These findings probably reflect properties of
fibrinogen as an acute phase reactant, although
some authors attributed this phenomenon to severe tissue
damage, vascular endothelial injury or a compensating
mechanism by the liver in response to increased con-
sumption (Higgins & Cousineau 1977; Sitprija et al.
1980; Lomar 1990; Pereira da Silva et al. 1995; Daher de
Francesco et al. 2002).
Endothelial cell injury and vasculitis are generally
accepted as major pathological characteristics of leptospi-
rosis. Vasculitis is a condition characterized by inflamma-
tion of the vessel wall with reactive damage to mural
structures causing endothelial cell injury. The clinical result
may lead to intravascular thrombosis, subsequent organ
infarction and dysfunction.
Lung samples of 12 humans, who died from leptospi-
rosis, showed stimulated vascular endothelium marked by
swelling of endothelial cells, an increase in pinocytotic
vesicles, and giant dense bodies in the cytoplasm of these
cells (Nicodemo et al. 1997). An experimental guinea pig
model of pulmonary haemorrhage showed no signs of
systemic vasculitis (Nally et al. 2004). Pulmonary endo-
thelial cell blebs were the only observation made. Immu-
nofluorescence showed the presence of IgM, IgG, IgA and
C3 along the alveolar basement membranes of the lungs,
possibly causing haemorrhage. Other guinea pig models
showed significant vascular damage with vascular conges-
tion and detached endothelial cells (Higgins & Cousineau
1977; de Brito et al. 1979; Pereira da Silva et al. 1995).
A marmoset monkey model, infected with Leptospira
interrogans serovar Copenhageni, showed microscopic
patterns of tissue reaction comparable with dose seen in
the severe forms of human leptospirosis. Besides intense
intra-alveolar haemorrhages, alveolar septal vessels were
congested and contained a higher number of megakaryo-
cytes than the controls. The liver showed mild intersti-
tial oedema, vascular congestion and focal necrosis
(Pereira et al. 2005).
The TTP and HUS are only scarcely reported in
leptospirosis and probably do not play a major clinical
role. However, the diagnosis may be missed due to lack of
diagnostic tools in developing countries, endemic for
leptospirosis. The clinical picture of these syndromes are
characterized by both thrombocytopenia and microangio-
pathic haemolytic anaemia without any other clinically
apparent cause. Some studies distinguish the two syn-
dromes with predominantly neurological abnormalities
without renal impairment in TTP, and renal failure
together with minimal or absent neurological symptoms in
HUS. Laing et al. (1990) described in a case report the
association between TTP and leptospirosis. The case
concerned a patient presented with progressive neurolog-
ical deterioration and haemolysis. Postmortem histology
Table 1 Expected results of screening tests in haemorrhagic dis-
orders
Defect BT
Platelet
count PT aPTT Fib D-dimer
Thrombocytopenia › fl N N N N
Thrombocytopathy › N N N N N
DIC › fl › › fl ›
Factor VII N N › N N N
Factor XI, IX, VIII N N N › N N
Mild hepatic disease N N › › N N
Severe hepatic disease › fl › › N N
Vasculopathies › N N › N N
BT, bleeding time; PT, prothrombin time; aPTT, activated partial
thromboplastin time; Fib, fibrinogen; DIC, disseminated intra-
vascular coagulation.
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showed the characteristic hyaline thrombi within small
vessels of the brain, heart, lung and kidney, a finding not
seen in DIC.
Impairment of renal functioning is one of the features of
HUS and is a commonly found symptom in leptospirosis.
Based on the findings of thrombocytopenia, fragmented red
blood cells, reticulocytosis, high serum FDPs and renal
failure the diagnosis of HUS in relation to leptospirosis was
published as case report (Hanvanich et al. 1985). Relative
to the frequent occurrence of renal failure in severe disease,
the finding of HUS is probably a rare phenomenon.
General aspects of haemostasis and infection-induced
coagulation activation
Basically haemostasis is a balanced system of procoagulant
and anticoagulant mechanisms, consisting of the following
parts: primary haemostasis, coagulation (secondary hae-
mostasis), anticoagulant mechanisms and fibrinolysis. The
formation of a haemostatic plug by adhesion and
aggregation of platelets in close concert with the endothe-
lium is considered the primary haemostasis. Secondary
haemostasis encompasses a series of protease-zymogen
reactions necessary to stabilize this haemostatic plug with
the formation of fibrin strands. This process is counterac-
ted by anticoagulant mechanisms, including the proteins C
and S and the antithrombin (AT)-heparin pathway. Finally,
the plug is degraded by plasmin-mediated cleavage of fibrin
strands during the process of fibrinolysis.
Coagulation activation and fibrin deposition during
inflammation can be seen as an important part of the host
defence of the body against, for example infectious
organisms, in order to limit the invading antigen and the
inflammatory response to a certain area (Levi et al. 2004b).
In humans, severe infection or sepsis invariably leads to
systemic coagulation activation, impairment of anticoagu-
lant mechanisms and inhibited fibrinolysis (Kinasewitz
et al. 2004; Levi & van der Poll 2004). In the worst case
scenario this may lead to DIC, which may besides
haemodynamic and metabolic derangements, contribute to
MOF (Levi & ten Cate 1999). Membrane components of
virtually all micro-organisms are able to induce this
syndrome.
The tissue factor pathway is the most important route
for activation of the coagulation cascade in DIC (Levi &
ten Cate 1999). A number of cells express tissue factor
throughout the body (Mann et al. 1998), for example,
circulating mononuclear cells when stimulated by proin-
flammatory cytokines (Osterud & Flaegstad 1983; Franco
et al. 2000). The majority of cells expressing tissue factor
are in tissues not in direct contact with blood, but
histological tissue factor appears to be present in all blood–
tissue barriers (Camerer et al. 1996). When exposed to
blood, tissue factor binds to factor VIIa. This complex
catalyses the conversion of factor X to Xa which eventually
leads to fibrin clot formation.
Inhibitors of coagulation include AT, proteins C and S
and tissue factor pathway inhibitor (TFPI). In severe
human sepsis AT and proteins C and S plasma levels are
markedly reduced (Mesters et al. 1996; Kessler et al. 1997;
Kinasewitz et al. 2004). There is some evidence that the
function of the TFPI system is impaired in patients with
DIC (Creasey et al. 1993). Animal models of severe
infection show activation of the fibrinolytic system, which
is eventually shut of by PAI-1 activity causing a net
procoagulant state (Levi et al. 1994; Biemond et al. 1995,
1997). This is in concert with severe human sepsis, where
non-survivors show besides derangements in coagulation
activation, a more pronounced suppression of the fibrin-
olytic system (van Gorp et al. 1999; Kinasewitz et al.
2004).
Platelets play an important role in inflammation-induced
coagulation activation as well. They can be activated
directly by endotoxins and proinflammatory mediators,
such as platelet-activating factor (PAF; Zimmerman et al.
2002; Levi et al. 2003). Once activated platelets start
expressing P-selectin on the membrane which mediates not
only the adherence of platelets to leucocytes and endot-
helial cells, but also the enhancement of tissue factor
expression on mononuclear cells (Shebuski & Kilgore
2002).
There is an increasing body of evidence that supports the
concept of an intensive crosstalk between inflammation
and coagulation. Activated coagulation proteases have
been shown to induce the release of (pro)inflammatory
cytokines, whereas some cytokines (Theilen et al. 2002)
elicit procoagulant effects (Levi et al. 2003).
Current insights in the pathogenesis of abnormal
haemostasis in leptospirosis
Primary haemostasis
Disorders of primary haemostasis are very common during
the course of many infectious diseases. In this regard,
thrombocytopenia is a well-documented feature in lepto-
spirosis, with a high incidence. The underlying mechanism
of thrombocytopenia is not always clear. It may be the
result of decreased thrombopoiesis, increased platelet
consumption because of immune or non-immune causes,
thrombocytopathy or a combination. Some authors sug-
gested that bone marrow suppression, due to a direct toxic
effect of Leptospira could be cause the observed thromb-
ocytopenia (Somers et al. 2003) or did not rule out the
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possibility (Nicodemo et al. 1990). Concerning non-
immune platelet destruction, one study explored the
possibility of platelet consumption because of DIC as an
explanation for the frequently observed thrombocytopenia
in leptospirosis. Based upon laboratory measurements the
authors concluded that there was no causal relationship
(Edwards et al. 1986). In general, it is assumed that
thrombocytopenia is mainly immune-mediated contribu-
ting to enhanced clearance. For leptospirosis in this regard,
some authors postulated that this phenomenon could be
attributed to a yet unknown platelet antibody (Kahn
1982); however, there are technical difficulties in the study
of such antibodies (Nicodemo et al. 1990). One case report
offered some evidence for immune-mediated platelet
destruction, as was shown by high titres of surface-bound
immunoglobulin, the complement factor C3d and the
beneficial response to treatment with methylprednisolone
and hydrocortisone (Davenport et al. 1989). Several other
studies demonstrated peripheral platelet destruction by
bone marrow aspirates, revealing hypercellularity and
increased megakaryocytes (Davenport et al. 1989; Turgut
et al. 2002). Another study suggested, based on human
postmortem lung fragments that the thrombocytopenia
was determined by activation, adhesion and aggregation of
platelets to stimulated vascular endothelium (Nicodemo
et al. 1997). Platelet surface receptors with high affinity for
subendothelium adhesion glycoproteins (e.g. von Wille-
brand) may facilitate this process. Indeed, an amorphous
substance was found, interposed between the endothelial
cells and platelets in places where the subendothelial
collagen was not exposed. No fibrin was found in the
platelet aggregates. An experimental guinea pig model by
Yang et al. (2006) showed evidence for platelet activation,
reflected by increased plasma levels 11-dehydrogenate
thromboxane B2 (11-DH-TXB2) that is considered a
sensitive marker. Aggregation of platelets and Kupffer cell
phagocytosis of platelets in the liver was another feature
found.
Several genes of L. interrogans were found to encode
proteins with close homology to animal proteins which
play an important role in haemostasis (Ren et al. 2003),
including a protein that resembles the mammalian PAF
acetylhydrolase (pafAH) and another protein that showed
similarity to von Willebrand factor type A domains (Vwa).
Also an orthologue of paraoxonase (Pon) was found,
which hydrolyses PAF through its arylesterase activity. It is
possible that each of these proteins contribute to haemo-
static chances in leptospirosis. In the same study, genes
were found encoding for haemolysins and sphingo-myel-
inase-like proteins. It is not clear whether these proteins
play a significant role in the pathogenesis of leptospirosis.
Coagulation test results are summarized in Table 2.
Secondary haemostasis
When mononuclear cells were stimulated in vitro by a
virulent or non-virulent strain of L. interrogans serovar
Icterohaemorrhagiae coagulant activity was observed,
measured by one-stage plasma recalcification time
(Miragliotta & Fumarola 1983). There was a significant
difference in degree of induction between the virulent and
non-virulent strains. Cells incubated with the virulent strain
developed significantly higher coagulant activation
expressed by shortening of the clotting time, than those cells
incubated with the non-virulent strain. Interestingly, there
was no coagulation activity observed in factor VII-deficient
blood. Based on these data the authors concluded that
mononuclear cells induced by (non-)virulent strains of
Leptospira expressed tissue factor-dependent procoagulant
activity. A small Indonesian cohort study revealed activated
coagulation, reflected by increased plasma levels of the
coagulation activation markers thrombin–antithrombin
complex (TAT) and fibrin fragments 1 and 2 (F1 + 2) in
severe human subjects (unpublished results). Increased
D-dimer plasma levels showed evidence for active fibrino-
lysis. In contrast, a guinea pig model showed a trend of
declining TAT complexes after inoculation of Leptospira
(Yang et al. 2006). This observation is surprising,
because TAT is a sensitive marker of coagulation activation.
In Gram-negative sepsis, circulating endotoxins play a
pivotal role by activating coagulation via the tissue factor
pathway (van Deventer et al. 1990; Thijs et al. 1993;
Baglin 1996; Gando et al. 1996). Endotoxins are lipo-
polysaccharide (LPS) constituents of the outer membrane
of Gram-negative micro-organisms. Leptospiral LPS has
structural, chemical and immunological properties resem-
bling those of Gram-negative bacterial LPS (Faine et al.
1999). Nevertheless, it is relatively non-toxic to cells or
animals, but large doses can cause haemorrhages in mice
(Faine et al. 1999). The possible mechanism of coagulation
activation in leptospirosis is illustrated in Figure 1.
Anticoagulation pathways
Upon activation of protein C by the thrombin–thrombo-
modulin complex activated protein C (APC) is a powerful
inhibitor of the coagulation cascade, acting in concert with
protein S. APC is believed to be not only a potent
anticoagulant, but also an enzyme that modulates a
number of inflammatory processes through direct cellular
or indirect pathways [the latter through interaction with
protease-activated receptors (PARs) or the endothelial
protein C receptor (EPCR)]. The nature and extent of these
inflammatory actions is the subject of ongoing research.
While proinflammatory cytokines may reduce the cellular
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expression of the cofactors thrombomodulin and EPCR,
diminishing the PC mechanism, in infectious disease in
general, a second mechanism may undermine this natural
anticoagulant system. In patients with severe leptospirosis
and significantly elevated concentrations of antiphosphol-
ipid antibodies (Rugman et al. 1991; Daher de Francesco
et al. 2002) the function of the protein C system may also
be inhibited (Marciniak & Romond 1989). Antithrombin,
a circulating serine protease inhibitor, is another important
inhibitor of the activated coagulation system. The third
anticoagulant pathway consists of TFPI, primarily synthe-
sized in the microvascular endothelium. Its anticoagulant
mechanism is due to quaternary complex formation with
factor X and tissue factor–factor VII, thereby impairing
coagulation. These pathways have never been studied in
leptospirosis.
Fibrinolysis
In the circulating blood the process of fibrinolysis is
important for limited proteolysis of cross-linked fibrin
molecules. Infection-associated coagulation activation is
Table 2 Results of tests of coagulation
Test and study reference
Mean value
Cases Controls
Platelets
Daher de Francesco et al. (2002;
decreased: <150 · 103/mm3)
69 (SD 65)
Edwards et al. (1986; decreased: <100 · 109/l)* 42.3 (SD 29.8)* 207.8 (67.2)
Jaroonvesama et al. (1975; 129–230 · 103/mm3) 135
Nicodemo et al. (1990; 150–450 · 103/mm3) 70
Edwards et al. (1986; decreased: £100 · 109/l) 125 (SD 84)
Edwards et al. (1982;
decreased: £100 · 103/mm3)
46.9 (SD 26.7)* 188.2 (SD 69.4)
Prothrombin time
Daher de Francesco et al. (2002; 12–14.4 s) 13.3 (SD 0.8)
Jaroonvesama et al. (1975; 15–16 s) 25.1
Edwards et al. (1986; no normal values denoted) 13.3 (SD 2.1)
Edwards et al. (1982; 13–15 s) 15.8 (SD 2)* 15.9 (SD 1.5)
Sitprija et al. (1980; 70–100%) 78.9 (SEM 0.9)
Activated partial thromboplastin time
Daher de Francesco et al. (2002; 32–38.4 s) 32.7 (SD 2.1)
Jaroonvesama et al. (1975; 55–69 s) 73
Edwards et al. (1986; no normal values denoted) 28.6 (SD 12.3)
Sitprija et al. (1980; 25–55 s) 33.4 (SEM 0.5)
Thrombin time
Daher de Francesco et al. (2002; 9.8–11 s) 11 (SD 1.4)
Jaroonvesama et al. (1975; 5–6 s) 6.9
Fibrinogen
Daher de Francesco et al. (2002; 150–380 mg/dl) 515 (SD 220)
Jaroonvesama et al. (1975; 306 mg/100 ml) 529
Sitprija et al. (1980; 200–400 mg/dl) 818 (SEM 57.6)
Fibrinogen degradation products (FDP)
Edwards et al. (1986; <7.5 lg/ml) 8.1 (SD 4.8)* 9.5 (SD 4.4)
Jaroonvesama et al. (1975; 6–9 lg/ml) 12.4
Sitprija et al. (1980; <0.5 mg/ml) 3.7 (SEM 0.39)
Factor V
Jaroonvesama et al. (1975; 130%) 77
Sitprija et al. (1980; 70–120%) 90.8 (SEM 0.9)
Factor VIII
Jaroonvesama et al. (1975; 120%) 113
Sitprija et al. (1980; 70–120%) 88.6 (SEM 1.3)
Factor X
Jaroonvesama et al. (1975; 130%) 113
*All thrombocytopenic patients.
Non-thrombocytopenic leptospirosis cases.
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followed by activation of the fibrinolytic system due to
increased levels of tissue plasminogen activator (tPA) and
urokinase plasminogen activator (uPA), followed by an
increase of PAI-1. The degree of rise in systemic PAI-1
concentration determines whether a net procoagulant state
occurs, such as in case of DIC (Biemond et al. 1995). Only
a limited amount of data exists about the activation of the
fibrinolytic system in leptospirosis. Elevated levels of fibrin
degradation products (FDP) in leptospirosis were reported
in a number of studies (Jaroonvesama et al. 1975; Higgins
& Cousineau 1977; Sitprija et al. 1980; Navarro & Kociba
1982; Edwards et al. 1986; Daher de Francesco et al.
2002). There are no studies focusing on regulatory path-
ways of fibrinolysis, like the PAI-1 protein.
Leptospirosis and the endothelial cell
As mentioned earlier, pathological findings points to the
endothelial cell to be important in the pathophysiology of
leptospirosis. The endothelial cell plays a crucial role in the
regulation of both coagulation and fibrinolysis (Keller et al.
2003). Endothelium is able to express tissue factor, von
Willebrand factor and a wide variety of cytokines in
reaction to various pathogens. Endothelial cells exposed to
a pathogen lose their anticoagulant properties, which
results in a net procoagulant state (Keller et al. 2003).
Increased levels of thrombomodulin found in an animal
model, may reflect endothelial cell injury in leptospirosis
(Yang et al. 2006) and point to soluble thrombomodulin as
a marker for endothelial damage. An other experimental
model found that intact Leptospires and leptospiral pept-
idoglycans activate cultured human endothelial cells,
reflected by an increased adhesiveness for neutrophilic
granulocytes (Dobrina et al. 1995). This resembles the
effects of LPS on endothelial cells.
The complete genomic sequencing of the virulent serovar
Lai identified a colA gene encoding for microbial collag-
enase (Ren et al. 2003). The authors proposed that
collagenase-mediated injury of the vascular endothelium
may contribute to the loss of haemostasis in human
leptospirosis.
Inflammatory response to Leptospira
Cytokines play an important role in the activation of the
coagulation cascade (Levi et al. 2003). Surface-exposed
membrane components, such as LPS, trigger a general host
immune response. Thus, far over 260 membrane-associ-
Figure 1 Mechanisms of coagulation activation in leptospirosis. (1) Amplification loops: (a) activation of factor IX by the tissue factor
(TF)–factor VIIa complex, generates additional factor Xa; (b) thrombin-induced factor XI activation, leading to additional factors IXa and
Xa; (c) activation of the essential co-factors V and VIII by thrombin. (2) Tissue factor expression by monocytes and endothelial cells.
Leptospiral lipopolysaccharide or other outer membrane components may induce cytokine release by monocytes and/or endothelial cells.
Both may induce TF expression and thereby induce coagulation activation, inhibition of anticoagulant pathways or fibrinolysis. (3) The
anticoagulant pathways: proteins C and S, antithrombin and TF pathway inhibitor. (4) The process of fibrinolysis breaks down cross-
linked fibrin molecules. Coagulation activation triggers the activation of the fibrinolytic system by increasing levels of tissue plasminogen
activator and urokinase plasminogen activator, followed by an increase of plasminogen activator inhibitor type-1. This is a strong inhibitor
of the fibrinolysis.
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ated proteins have been identified in Leptospira, and for
most of these the relevance with regard to an immunogenic
reaction remains to be established (Nascimento et al.
2004). Six surface-exposed lipoproteins have been identi-
fied, of which LipL32 and LipL21 are of most interest,
because they are found in all pathogenic Leptospira
(Cullen et al. 2002, 2005). Both leptospiral LPS and
LipL32 interact with the Toll-like receptor (TLR)-2 and
CD14 to signal to activated macrophages (Werts et al.
2001). LPS of Gram-negative bacteria interact predomin-
antly with the TLR4. In contrast, another study found a
protective role for the TLR4 in an experimental leptospi-
rosis mouse model (Viriyakosol et al. 2006), which suggest
this receptor is of importance for leptospiral LPS. Injected
tumour necrosis factor (TNF)-a activated the coagulation
system via the tissue factor pathway in healthy volunteers
(Bauer et al. 1989; van der Poll et al. 1990; van Deventer
et al. 1990). Elevated plasma concentrations of TNF-a
were found in patients affected by leptospirosis (Estavoyer
et al. 1991) and higher TNF-a levels were associated with
disease severity and mortality (Tajiki & Salomao 1996).
Leptospiral peptidoglycans induce TNF-a release from
peripheral blood mononuclear cells in a dose-dependant
manner in vitro (Cinco et al. 1996). Other in vitro
experiments showed that the inflammatory response was
also mediated primarily by a Th1 response, involved in
cellular immunity. Increased levels of interferon (IFN)-c,
interleukin (IL)-12p40, IL-12 and TNF-a were found after
stimulation with heat-killed Leptospira (de Fost et al.
2003; Klimpel et al. 2003). Leptospira interrogans glyco-
lipoprotein (GLP) was found to induce cellular production
of TNF-a and IL-10 in peripheral blood mononuclear cell
cultured from healthy donors (Diament et al. 2002).
Conclusion and discussion
Leptospirosis is one of the world’s most prevalent zoo-
noses, with a clinical picture varying from mild to
potentially life-threatening disease, in which haemostatic
derangements play a central role. Despite these facts
leptospirosis is a neglected disease, which explains that
many crucial aspects concerning its pathogenesis remain
unanswered. Besides antibiotic therapy, which is the
cornerstone of treatment, we urgently need to improve
supportive treatment, especially for cases with life-threat-
ening bleeding complications.
From the studies reviewed we may also conclude that in
leptospirosis, as in other infectious disease, the bleeding
tendency is the result of a dysbalance in the haemostatic
equilibrium, although it is unclear how this dysbalance is
triggered and what inflammatory and coagulation proteins
are involved. The haemostatic dysbalance may lead to DIC,
but no human studies with modern, sensitive assays have
been performed to elucidate this question. DIC is a clinical
syndrome, and only a combination of laboratory markers
can establish or rule out the diagnosis (Levi & ten Cate
1999). Ascertain such a syndrome is important to assess the
potential role of new treatment options available in this
regard.
It would be premature to speculate what is the origin of
the bleeding. However, in several studies the endothelial
cell seems to be one of the target cells in leptospirosis. After
infection the endothelial cell may loose its antithrombotic
properties and we hypothesize that this might well be the
link to an out-of-balance coagulation cascade. The
endothelial cell may influence haemostasis due to stimula-
tion of cytokines in concert with, e.g. circulating lympho-
cytes or platelets or by direct effects of the invading
micro-organism, i.e. Leptospira. Ample evidence stress the
importance of the endothelium as the conductor of the
orchestra of procoagulant and anticoagulant pathways
(Levi et al. 2002; Keller et al. 2003).
To understand the haemorrhagic complications of
leptospirosis, there is an urgent need for prospective
studies. Efforts should be made to enrol both mild and
severe cases in all stages of disease, using case record forms
to be able to relate clinical signs and clinical outcome with
laboratory disturbances. Sensitive laboratory tests avail-
able, focusing on the different involved pathways should be
used. Studies should address the role of the endothelium
because its possible central role in the pathogenesis of
leptospirosis as posed here. Emphasis should be put on
identifying involved (pro)inflammatory cytokines, given
the intensive crosstalk between coagulation and inflam-
mation. Finally, contributing factors-like age, gender and
genetic profile should be taken into account. Such studies
will provide us the data necessary to improve supportive
and therapeutic management strategies to treat this
potentially fatal disease.
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Quel rôle ont les troubles de la coagulation dans la pathogénie de la leptospirose?
La leptospirose est une zoonose rencontrée à l’échelle mondiale, propagée par l’urine des animaux infectés. C’est un problème majeur de santé publique,
particulièrement dans les pays en voie de développement où les circonstances pour la transmission sont les plus favorables. L’aspect clinique varie d’une
maladie bénigne à une maladie sévère avec des troubles hémostatiques et une déficience de plusieurs organes menant au décès. Bien que les complications
hémorragiques de la maladie sévère soient sérieuses, la pathophysiologie est à peine élucidée. Les mécanismes complexes impliqués dans l’activation de
la coagulation induite par l’inflammation ont été intensivement étudiés dans diverses maladies infectieuses, i.e. sepsis à gram négatif. L’activation de la
coagulation médiée par le facteur du tissu, les déficiences de l’anticoagulant et les voies métaboliques fibrinolytiques en étroite corrélation avec le réseau
des cytokines semblent être importants. Mais pour la leptospirose humaine, les données demeurent limitées. En raison de l’intérêt croissant pour ce
domaine, l’impact de la leptospirose et la disponibilité de nouvelles stratégies thérapeutiques, nous avons passé en revue l’évidence concernant le rôle de
la coagulation dans la leptospirose et fournissons des suggestions pour la recherche future.
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‘Qué papel juegan los desórdenes de coagulación en la patogénesis de la leptoespirosis?
La leptoespirosis es una zoonosis mundialmente distribuida, diseminada por la orina de animales infectados. Es un importante problema de salud
pública, especialmente en paı́ses en vı́as de desarrollo, en donde las circunstancias de transmisión son las más favorables. El cuadro clı́nico varı́a desde la
enfermedad leve a la severa, con trastornos hemostáticos y fallo multiorgánico siendo eventualmente letal. Aunque las complicaciones hemorrágicas de
la enfermedad severa son serias, la patofisiologı́a raramente es elucidada. Se han estudiado extensivamente los complejos mecanismos involucrados en la
activación de la coagulación inducida por la inflamación en varias enfermedades infecciosas, como es el caso de la sepsis por gram negativos. Se cree que
son importantes la activación de la coagulación mediada por factores tisulares, la alteración de las vı́as fibrinolı́tixca y anticoagulatoria, conjuntamente
con la alteración de la red de citocinas. Pero en el caso de la leptoespirosis humana, los datos siguen siendo limitados. Debido al creciente interés en esta
área, el impacto de la leptoespirosis y la disponibilidad de nuevas estrategias terapéuticas, hemos revisado la evidencia con respecto al papel de la
coagulación en la leptoespirosis y damos sugerencias para futuros estudios.
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